Search Results
You are looking at 1 - 5 of 5 items for
- Author: Paola De Marco x
- Refine by access: All content x
Search for other papers by Paola De Marco in
Google Scholar
PubMed
Search for other papers by Enrica Romeo in
Google Scholar
PubMed
Search for other papers by Adele Vivacqua in
Google Scholar
PubMed
Search for other papers by Roberta Malaguarnera in
Google Scholar
PubMed
Search for other papers by Sergio Abonante in
Google Scholar
PubMed
Search for other papers by Francesco Romeo in
Google Scholar
PubMed
Search for other papers by Vincenzo Pezzi in
Google Scholar
PubMed
Search for other papers by Antonino Belfiore in
Google Scholar
PubMed
Search for other papers by Marcello Maggiolini in
Google Scholar
PubMed
Search for other papers by Paola De Marco in
Google Scholar
PubMed
Search for other papers by Enrica Romeo in
Google Scholar
PubMed
Search for other papers by Adele Vivacqua in
Google Scholar
PubMed
Regional Hospital Cosenza, Italy
Endocrinology Department of Health, University Magna Graecia of Catanzaro, Catanzaro, Italy
Search for other papers by Roberta Malaguarnera in
Google Scholar
PubMed
Regional Hospital Cosenza, Italy
Endocrinology Department of Health, University Magna Graecia of Catanzaro, Catanzaro, Italy
Search for other papers by Sergio Abonante in
Google Scholar
PubMed
Regional Hospital Cosenza, Italy
Endocrinology Department of Health, University Magna Graecia of Catanzaro, Catanzaro, Italy
Search for other papers by Francesco Romeo in
Google Scholar
PubMed
Search for other papers by Vincenzo Pezzi in
Google Scholar
PubMed
Regional Hospital Cosenza, Italy
Endocrinology Department of Health, University Magna Graecia of Catanzaro, Catanzaro, Italy
Search for other papers by Antonino Belfiore in
Google Scholar
PubMed
Search for other papers by Marcello Maggiolini in
Google Scholar
PubMed
Elevated insulin levels have been associated with an increased cancer risk as well as with aggressive and metastatic cancer phenotypes characterized by a poor prognosis. Insulin stimulates the proliferation, migration, and invasiveness of cancer cells through diverse transduction pathways, including estrogen signaling. As G protein estrogen receptor 1 (GPER1) mediates rapid cell responses to estrogens, we evaluated the potential of insulin to regulate GPER1 expression and function in leiomyosarcoma cancer cells (SKUT-1) and breast cancer-associated fibroblasts (CAFs), which were used as a model system. We found that insulin transactivates the GPER1 promoter sequence and increases the mRNA and protein expression of GPER1 through the activation of the PRKCD/MAPK1/c-Fos/AP1 transduction pathway, as ascertained by means of specific pharmacological inhibitors and gene-silencing experiments. Moreover, cell migration triggered by insulin occurred through GPER1 and its main target gene CTGF, whereas the insulin-induced expression of GPER1 boosted cell-cycle progression and the glucose uptake stimulated by estrogens. Notably, a positive correlation between insulin serum levels and GPER1 expression was found in cancer fibroblasts obtained from breast cancer patients. Altogether, our data indicate that GPER1 may be included among the complex network of transduction signaling triggered by insulin that drives cells toward cancer progression.
Search for other papers by Paola Sperone in
Google Scholar
PubMed
Search for other papers by Anna Ferrero in
Google Scholar
PubMed
Search for other papers by Fulvia Daffara in
Google Scholar
PubMed
Search for other papers by Adriano Priola in
Google Scholar
PubMed
Search for other papers by Barbara Zaggia in
Google Scholar
PubMed
Search for other papers by Marco Volante in
Google Scholar
PubMed
Search for other papers by Daniele Santini in
Google Scholar
PubMed
Search for other papers by Bruno Vincenzi in
Google Scholar
PubMed
Search for other papers by Giuseppe Badalamenti in
Google Scholar
PubMed
Search for other papers by Chiara Intrivici in
Google Scholar
PubMed
Search for other papers by Sabrina Del Buono in
Google Scholar
PubMed
Search for other papers by Silvia De Francia in
Google Scholar
PubMed
Search for other papers by Emmanouil Kalomirakis in
Google Scholar
PubMed
Search for other papers by Riccardo Ratti in
Google Scholar
PubMed
Search for other papers by Alberto Angeli in
Google Scholar
PubMed
Search for other papers by Luigi Dogliotti in
Google Scholar
PubMed
Search for other papers by Mauro Papotti in
Google Scholar
PubMed
Search for other papers by Massimo Terzolo in
Google Scholar
PubMed
Search for other papers by Alfredo Berruti in
Google Scholar
PubMed
Adrenocortical carcinoma (ACC) is a rare neoplasm characterized by poor prognosis. First-line systemic treatments in advanced disease include mitotane, either alone or in combination with chemotherapy. Studies evaluating second-line therapy options have obtained disappointing results. This trial assessed the activity and toxicity of gemcitabine plus metronomic fluoropyrimidines in heavily pretreated advanced ACC patients. From 1998 to 2008, 28 patients with advanced ACC progressing after mitotane plus one or two systemic chemotherapy lines were enrolled. They received a combination of i.v. gemcitabine (800 mg/m2, on days 1 and 8, every 21 days) and i.v. 5-fluorouracil protracted infusion (200 mg/m2/daily without interruption until progression) in the first six patients, or oral capecitabine (1500 mg/daily) in the subsequent patients. Mitotane administration was maintained in all cases. The rate of non-progressing patients after 4 months of treatment was 46.3%. A complete response was observed in 1 patient (3.5%); 1 patient (3.5%) obtained a partial regression, 11 patients (39.3%) obtained a disease stabilization and 15 patients (53.7%) progressed. Treatment was well tolerated, with grade III and IV toxicities consisting of leukopenia in six patients (21.4%), thrombocytopenia in one patient (3.5%), and mucositis in one patient (3.5%). Median time to progression and overall survival in the patient population were 5.3 (range: 1–43) and 9.8 months (range: 3–73) respectively. Gemcitabine plus metronomic fluoropyrimidines is a well-tolerated and moderately active regimen in heavily pretreated ACC patients.
Search for other papers by Massimo Terzolo in
Google Scholar
PubMed
Search for other papers by Giuseppe Reimondo in
Google Scholar
PubMed
Search for other papers by Paola Berchialla in
Google Scholar
PubMed
Search for other papers by Emanuele Ferrante in
Google Scholar
PubMed
Search for other papers by Elena Malchiodi in
Google Scholar
PubMed
Search for other papers by Laura De Marinis in
Google Scholar
PubMed
Search for other papers by Rosario Pivonello in
Google Scholar
PubMed
Search for other papers by Silvia Grottoli in
Google Scholar
PubMed
Search for other papers by Marco Losa in
Google Scholar
PubMed
Search for other papers by Salvatore Cannavo in
Google Scholar
PubMed
Search for other papers by Diego Ferone in
Google Scholar
PubMed
Search for other papers by Marcella Montini in
Google Scholar
PubMed
Search for other papers by Marta Bondanelli in
Google Scholar
PubMed
Search for other papers by Ernesto De Menis in
Google Scholar
PubMed
Search for other papers by Chiara Martini in
Google Scholar
PubMed
Search for other papers by Efisio Puxeddu in
Google Scholar
PubMed
Search for other papers by Antonino Velardo in
Google Scholar
PubMed
Search for other papers by Alessandro Peri in
Google Scholar
PubMed
Search for other papers by Marco Faustini-Fustini in
Google Scholar
PubMed
Search for other papers by Patrizia Tita in
Google Scholar
PubMed
Search for other papers by Francesca Pigliaru in
Google Scholar
PubMed
Search for other papers by Giulia Peraga in
Google Scholar
PubMed
Search for other papers by Giorgio Borretta in
Google Scholar
PubMed
Search for other papers by Carla Scaroni in
Google Scholar
PubMed
Search for other papers by Nicoletta Bazzoni in
Google Scholar
PubMed
Search for other papers by Antonio Bianchi in
Google Scholar
PubMed
Search for other papers by Alessandro Berton in
Google Scholar
PubMed
Search for other papers by Andreea Liliana Serban in
Google Scholar
PubMed
Search for other papers by Roberto Baldelli in
Google Scholar
PubMed
Search for other papers by Letizia Maria Fatti in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by Maura Arosio in
Google Scholar
PubMed
Search for other papers by for the Italian Study Group of Acromegaly in
Google Scholar
PubMed
It is debated if acromegalic patients have an increased risk to develop malignancies. The aim of the present study was to assess the standardized incidence ratios (SIRs) of different types of cancer in acromegaly on a large series of acromegalic patients managed in the somatostatin analogs era. It was evaluated the incidence of cancer in an Italian nationwide multicenter cohort study of 1512 acromegalic patients, 624 men and 888 women, mean age at diagnosis 45 ± 13 years, followed up for a mean of 10 years (12573 person-years) in respect to the general Italian population. Cancer was diagnosed in 124 patients, 72 women and 52 men. The SIRs for all cancers was significantly increased compared to the general Italian population (expected: 88, SIR 1.41; 95% CI, 1.18–1.68, P < 0.001). In the whole series, we found a significantly increased incidence of colorectal cancer (SIR 1.67; 95% CI, 1.07–2.58, P = 0.022), kidney cancer (SIR 2.87; 95% CI, 1.55–5.34, P < 0.001) and thyroid cancer (SIR 3.99; 95% CI, 2.32–6.87, P < 0.001). The exclusion of 11 cancers occurring before diagnosis of acromegaly (all in women) did not change remarkably the study outcome. In multivariate analysis, the factors significantly associated with an increased risk of malignancy were age and family history of cancer, with a non-significant trend for the estimated duration of acromegaly before diagnosis. In conclusion, we found evidence that acromegaly in Italy is associated with a moderate increase in cancer risk.
Search for other papers by Régia Caroline Peixoto Lira in
Google Scholar
PubMed
Search for other papers by Paola Fernanda Fedatto in
Google Scholar
PubMed
Search for other papers by David Santos Marco Antonio in
Google Scholar
PubMed
Search for other papers by Letícia Ferro Leal in
Google Scholar
PubMed
Search for other papers by Carlos Eduardo Martinelli in
Google Scholar
PubMed
Search for other papers by Margaret de Castro in
Google Scholar
PubMed
Search for other papers by Silvio Tucci in
Google Scholar
PubMed
Search for other papers by Luciano Neder in
Google Scholar
PubMed
Search for other papers by Leandra Ramalho in
Google Scholar
PubMed
Search for other papers by Ana Luiza Seidinger in
Google Scholar
PubMed
Search for other papers by Izilda Cardinalli in
Google Scholar
PubMed
Search for other papers by Maria José Mastellaro in
Google Scholar
PubMed
State University of Campinas (UNICAMP), CampinasSão Paulo, Brazil
Search for other papers by José Andres Yunes in
Google Scholar
PubMed
State University of Campinas (UNICAMP), CampinasSão Paulo, Brazil
Search for other papers by Silvia Regina Brandalise in
Google Scholar
PubMed
Search for other papers by Luiz Gonzaga Tone in
Google Scholar
PubMed
Search for other papers by Sonir Roberto Rauber Antonini in
Google Scholar
PubMed
Search for other papers by Carlos Alberto Scrideli in
Google Scholar
PubMed
Deregulation of the IGF system observed in human tumors indicates a role in malignant cell transformation and in tumor cell proliferation. Although overexpression of the IGF2 and IGF1R genes was described in adrenocortical tumors (ACTs), few studies reported their profiles in pediatric ACTs. In this study, the IGF2 and IGF1R expression was evaluated by RT-qPCR according to the patient’s clinical/pathological features in 60 pediatric ACT samples, and IGF1R protein was investigated in 45 samples by immunohistochemistry (IHC). Whole transcriptome and functional assays were conducted after IGF1R inhibition with OSI-906 in NCI-H295A cell line. Significant IGF2 overexpression was found in tumor samples when compared with non-neoplastic samples (P<0.001), significantly higher levels of IGF1R in patients with relapse/metastasis (P=0.031) and moderate/strong IGF1R immunostaining in 62.2% of ACTs, but no other relationship with patient survival and clinical/pathological features was observed. OSI-906 treatment downregulated genes associated with MAPK activity, induced limited reduction of cell viability and increased the apoptosis rate. After 24h, the treatment also decreased the expression of genes related to the steroid biosynthetic process, the protein levels of the steroidogenic acute regulatory protein (STAR), and androgen secretion in cell medium, supporting the role of IGF1R in steroidogenesis of adrenocortical carcinoma cells. Our data showed that the IGF1R overexpression could be indicative of aggressive ACTs in children. However, in vitro treatments with high concentrations of OSI-906 (>1μM) showed limited reduction of cell viability, suggesting that OSI-906 alone could not be a suitable therapy to abolish carcinoma cell growth.
